Fate Therapeutics Inc. (FATE) and KemPharm Inc. (NASDAQ:KMPH) Comparison side by side – The EN Herald

This is therefore a contrasting of the risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation in Fate Therapeutics Inc. (NASDAQ:FATE) and KemPharm Inc. (NASDAQ:KMPH). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 represents Fate Therapeutics Inc. (NASDAQ:FATE) and KemPharm Inc. (NASDAQ:KMPH)s net margins, return on equity and return on assets.

Volatility & Risk

A 1.62 beta indicates that Fate Therapeutics Inc. is 62.00% more volatile compared to S&P 500. Competitively, KemPharm Inc.s beta is 1.33 which is 33.00% more volatile than S&P 500.

Liquidity

Fate Therapeutics Inc.s Current Ratio is 6.4 while its Quick Ratio is 6.4. On the competitive side is, KemPharm Inc. which has a 1 Current Ratio and a 1 Quick Ratio. Fate Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to KemPharm Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Fate Therapeutics Inc. and KemPharm Inc.

Fate Therapeutics Inc. has a 30.49% upside potential and a consensus price target of $23.75. Meanwhile, KemPharm Inc.s average price target is $1.05, while its potential upside is 28.83%. Based on the analysts view we can conclude, Fate Therapeutics Inc. is looking more favorable than KemPharm Inc.

Institutional and Insider Ownership

Institutional investors owned 98.8% of Fate Therapeutics Inc. shares and 33.5% of KemPharm Inc. shares. Fate Therapeutics Inc.s share owned by insiders are 0.9%. Comparatively, KemPharm Inc. has 0.5% of its share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Fate Therapeutics Inc. had bullish trend while KemPharm Inc. had bearish trend.

Summary

On 8 of the 9 factors Fate Therapeutics Inc. beats KemPharm Inc.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. The companys immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf T-cell immunotherapies; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Here is the original post:
Fate Therapeutics Inc. (FATE) and KemPharm Inc. (NASDAQ:KMPH) Comparison side by side - The EN Herald